Jove
Visualize
Contact Us
JoVE
x logofacebook logolinkedin logoyoutube logo
ABOUT JoVE
OverviewLeadershipBlogJoVE Help Center
AUTHORS
Publishing ProcessEditorial BoardScope & PoliciesPeer ReviewFAQSubmit
LIBRARIANS
TestimonialsSubscriptionsAccessResourcesLibrary Advisory BoardFAQ
RESEARCH
JoVE JournalMethods CollectionsJoVE Encyclopedia of ExperimentsArchive
EDUCATION
JoVE CoreJoVE BusinessJoVE Science EducationJoVE Lab ManualFaculty Resource CenterFaculty Site
Terms & Conditions of Use
Privacy Policy
Policies

Filters

Catherine Lai

Showing results (71-80 of 84) with videos related to

Pageof 9
Sort By:
Frontiers in Oncology|January 31, 2019
Molecular Measurable Residual Disease Testing of Blood During AML Cytotoxic Therapy for Early Prediction of Clinical ResponseHong Yuen Wong, Anthony D Sung, Katherine E Lindblad, et al.
Blood Advances|January 28, 2020
Highly multiplexed proteomic assessment of human bone marrow in acute myeloid leukemiaHaydar Çelik, Katherine E Lindblad, Bogdan Popescu, et al.
European Journal of Haematology|December 27, 2024
Tumor Lysis Syndrome in Acute Myeloid Leukemia Patients Treated With a Venetoclax Based RegimenMargaret Rowe, Daria Babushok, Martin Carroll, et al.
The New England Journal of Medicine|January 21, 2026
Sacituzumab Govitecan plus Pembrolizumab for Advanced Triple-Negative Breast CancerSara M Tolaney, Evandro de Azambuja, Kevin Kalinsky, et al.
JACC. Advances|June 18, 2026
Cardiovascular Events in Patients With Acute Myeloid Leukemia Treated With Venetoclax: A Multicenter Cohort StudySabin Filimon, Azin Ghamari, Azin Vakilpour, et al.
Blood Advances|January 31, 2025
Evolving racial/ethnic disparities in AML survival in the novel therapy eraXin Wang, Phyllis A Gimotty, Andrew H Matthews, et al.
Journal for Immunotherapy of Cancer|January 12, 2022
Pembrolizumab and decitabine for refractory or relapsed acute myeloid leukemiaMeghali Goswami, Gege Gui, Laura W Dillon, et al.
American Journal of Hematology|June 19, 2023
Real-world effectiveness of intensive chemotherapy with 7&3 versus venetoclax and hypomethylating agent in acute myeloid leukemiaAndrew H Matthews, Alexander E Perl, Selina M Luger, et al.
Blood Cancer Discovery|July 14, 2021
Personalized Single-Cell Proteogenomics to Distinguish Acute Myeloid Leukemia from Non-Malignant Clonal HematopoiesisLaura W Dillon, Jack Ghannam, Chidera Nosiri, et al.
Blood Advances|December 14, 2022
Diminished humoral and cellular responses to SARS-CoV-2 vaccines in patients with chronic lymphocytic leukemiaChaitra Ujjani, Ted A Gooley, Stephen E Spurgeon, et al.
Pageof 9

Showing results (71-80 of 84) with videos related to

Sort By:
Pageof 9
Frontiers in Oncology|January 31, 2019
Molecular Measurable Residual Disease Testing of Blood During AML Cytotoxic Therapy for Early Prediction of Clinical ResponseHong Yuen Wong, Anthony D Sung, Katherine E Lindblad, et al.
Blood Advances|January 28, 2020
Highly multiplexed proteomic assessment of human bone marrow in acute myeloid leukemiaHaydar Çelik, Katherine E Lindblad, Bogdan Popescu, et al.
European Journal of Haematology|December 27, 2024
Tumor Lysis Syndrome in Acute Myeloid Leukemia Patients Treated With a Venetoclax Based RegimenMargaret Rowe, Daria Babushok, Martin Carroll, et al.
The New England Journal of Medicine|January 21, 2026
Sacituzumab Govitecan plus Pembrolizumab for Advanced Triple-Negative Breast CancerSara M Tolaney, Evandro de Azambuja, Kevin Kalinsky, et al.
JACC. Advances|June 18, 2026
Cardiovascular Events in Patients With Acute Myeloid Leukemia Treated With Venetoclax: A Multicenter Cohort StudySabin Filimon, Azin Ghamari, Azin Vakilpour, et al.
Blood Advances|January 31, 2025
Evolving racial/ethnic disparities in AML survival in the novel therapy eraXin Wang, Phyllis A Gimotty, Andrew H Matthews, et al.
Journal for Immunotherapy of Cancer|January 12, 2022
Pembrolizumab and decitabine for refractory or relapsed acute myeloid leukemiaMeghali Goswami, Gege Gui, Laura W Dillon, et al.
American Journal of Hematology|June 19, 2023
Real-world effectiveness of intensive chemotherapy with 7&3 versus venetoclax and hypomethylating agent in acute myeloid leukemiaAndrew H Matthews, Alexander E Perl, Selina M Luger, et al.
Blood Cancer Discovery|July 14, 2021
Personalized Single-Cell Proteogenomics to Distinguish Acute Myeloid Leukemia from Non-Malignant Clonal HematopoiesisLaura W Dillon, Jack Ghannam, Chidera Nosiri, et al.
Blood Advances|December 14, 2022
Diminished humoral and cellular responses to SARS-CoV-2 vaccines in patients with chronic lymphocytic leukemiaChaitra Ujjani, Ted A Gooley, Stephen E Spurgeon, et al.
Pageof 9